TRANSCODE THERAPEUTICS INC (RNAZ) Stock Income Statement
NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 15.54M | 15.66M | 19.42M | 18.63M | 6.15M | |||
| Research and Development | 10.17M | 9.71M | 12.26M | 10.23M | 2.75M | |||
| Selling, General, and Administrative Expenses | 5.38M | 5.95M | 7.16M | 8.40M | 3.40M | |||
| Operating Income | -15.54M | -15.66M | -19.42M | -18.63M | -6.15M | |||
| Interest Income/Expense | -45.50K | -83.20K | -50.60K | -11.60K | -961.40K | |||
| Other Income/Expense | -9.93M | -1.01M | 923.00K | 1.08M | 272.20K | |||
| Income Before Taxes | -25.51M | -16.75M | -18.55M | -17.57M | -6.84M | |||
| Income Tax | N/A | 0.00 | N/A | N/A | N/A | |||
| Net Income | -25.54M | -16.79M | -18.55M | -17.57M | -6.84M | |||
| EBITDA | -14.99M | -15.13M | -19.30M | -18.54M | -6.11M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -445.90 | -1.32K | -103.61 | -1.08K | -651.75 | |||
| Non GAAP EPS | N/A | -197.50 | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD